oxaliplatin / Generic mfg. - LARVOL DELTA

MATRIX: Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2025 ➔ Nov 2025

Enrollment open • Trial initiation date • Colorectal Cancer • Oncology • Solid Tumor

RASolute 302: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P3 | N=501 | Active, not recruiting | Sponsor: Revolution Medicines, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12) (ASH 2025) - P1/2 | "The study consists of three arms: Arm 1: Birelentinib + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Arm 2: Birelentinib + R-GemOx (rituximab, gemcitabine, oxaliplatin) for 8 cycles. Arm 3: Birelentinib + BR (rituximab, bendamustine) for 6 cycles...Pharmacokinetic analyses will be conducted as secondary objectives in both parts of the study. Patient enrollment for this study commenced in July 2025 and is currently ongoing."

Clinical • Combination therapy • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Optim.AI™ 2.0: Functional precision platform for identifying effective immunotherapy combinations in DLBCL (ASH 2025) - "PBMCs were added to tumor cells at a fixed effector-to-target ratio, and Optim.AI 2.0 combinatorial drug sensitivity testing plates were applied to the co-culture system, with up to 12 FDA-approved drugs, including monoclonal antibodies (rituximab, obinutuzumab), antibody-drug conjugates (polatuzumab), bispecific antibodies (epcoritamab, glofitamab), targeted small-molecule inhibitors (venetoclax, everolimus, zanubrutinib), and cytotoxic chemotherapies (gemcitabine, oxaliplatin, cyclophosphamide, doxorubicin). This study demonstrates the feasibility of Optim.AI™ 2.0, an enhanced co-culture-based platform which provides a physiologically relevant and scalable approach to functionally evaluate immunotherapy drug sets. With further validation, Optim.AI™ 2.0 holds strong potential to support clinical decision-making and expand the use of immunotherapies in DLBCL."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Sarcoma • Solid Tumor

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma (ASH 2025) - " Pts with R/R NHL who underwent leukapheresis received pre-treatment with obinutuzumab prior to the first dose of glofitamab. Based on disease progression status, pts received glofitamab monotherapy or glofitamab combined with gemcitabine + oxaliplatin/ BTK inhibitor/ methotrexate regimens prior to CAR-T infusion... Glofitamab bridging therapy prior to CAR-T demonstrated promising efficacy in pts with high-risk NHL, without significant safety concerns or detrimental impact on CAR-T cell kinetics. This study provides preliminary evidence for redefining therapeutic paradigms in non-Hodgkin lymphoma, particularly PCNSL, supporting further investigation through expanded validation cohorts and longitudinal outcomes assessment."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • TP53

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia (ASH 2025) - P2 | "These findings provide a strong rationale for combining ruxolitinib with P-Gemox (pegaspargase, gemcitabine, and oxaliplatin) to improve outcomes in ANKL. This regimen appears to be an effective and well-tolerated induction strategy while bridging to allo-HSCT. These preliminary findings warrant further evaluation in larger, prospective studies."

Clinical • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Fibrosis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Influenza • Leukemia • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases

Establishment of a prognostic model for diffuse large B-cell lymphoma based on mitochondrial energy metabolism-related genes (ASH 2025) - "Drug sensitivity prediction further revealed that high-risk patients may respond better to cisplatin and oxaliplatin but show reduced sensitivity to venetoclax. In summary, this study established a novel MMRG-based prognostic model that enables precise risk stratification and reveals key links between mitochondrial metabolism and the immune landscape in DLBCL. These findings provide valuable insights for individualized prognosis evaluation and the development of metabolism-immune targeted therapies."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • ACSL5 • ADH1A • ASXL1 • CPT1A • DOT1L • MCL1 • PLK1

The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. (PubMed, Sci Adv) - "These events are guided by the guanosine monophosphate (GMP)-producing enzymes inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthase (GMPS), the expression of which correlated with that of matrisomal and DNA repair genes in samples from patients with PDAC. We propose that targeting ECM-driven metabolic processes, such as the enhanced IMPDH activity, may be an effective therapeutic approach for patients with PDAC to bypass the negative side effects of direct targeting of the ECM itself."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Dual Cardiotoxicity of Capecitabine: Coronary Vasospasm and QT Prolongation in a Patient with Gastric Adenocarcinoma. (PubMed, JACC Case Rep) - "This case illustrates the dual cardiotoxicity of capecitabine, with both vasospastic angina and QT prolongation."

Journal • Cardiovascular • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pain • Pulmonary Disease • Solid Tumor

Impact of Neoadjuvant Chemotherapy on Perioperative Tumor Marker Dynamics and Postoperative Recovery in Patients Undergoing Laparoscopic Radical Resection for Rectal Cancer. (PubMed, J Gastrointest Cancer) - "Neoadjuvant chemotherapy prior to laparoscopic radical resection for rectal cancer was associated with improved anus preservation, enhanced postoperative recovery, and greater biochemical and functional benefits without increasing major complication rates, although it was linked to higher hematologic adverse events and postoperative declines in immune cell counts."

Biomarker • Journal • Retrospective data • Colorectal Cancer • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Rectal Cancer • Solid Tumor • CA 19-9 • CD4 • CD8

Microglial macrophage-derived ds-HMGB1 in DRG orchestrates neuropathic pain through immune-neural signaling. (PubMed, Cell Rep) - "Here, we report that the pro-inflammatory disulfide isoform of high-mobility group box 1 (ds-HMGB1) is a key mediator of oxaliplatin-induced neuropathic pain, with DRG microglia-like tissue-resident macrophages (M-TRMφs) as its primary reservoir...M-TRMφ-derived ds-HMGB1 orchestrates neuropathic pain through pyroptotic release and TLR4/TRPV1 signaling in a redox-regulated macrophage-neuron axis in the DRG. ds-HMGB1 emerges as a potential biomarker and therapeutic target in CIPN."

IO biomarker • Journal • Neuralgia • Oncology • Pain • Peripheral Neuropathic Pain • HMGB1 • PDIA3 • TLR4 • TRPV1

BE screen reveals METTL3 S2 dephosphorylation sensitizes gastric cancer cells to oxaliplatin by interfering METTL3-eIF3H interaction. (PubMed, Sci Adv) - "In summary, base editor screen provides a versatile approach for exploring the role of phosphorylation sites in cancer chemotherapy. The METTL3-eIF3H interaction may serve as a potential therapeutic target."

Journal • Gastric Cancer • Oncology • Solid Tumor • BRD4 • EIF3H • METTL3 • SERPINE2

Trilaciclib for the prevention of chemotherapy-induced myelosuppression: A systematic review and meta-analysis (ASH 2025) - "Chemotherapy regimens were heterogeneous and included etoposide-platinum (E/P) (either cisplatin or carboplatin) (n=5), gemcitabine/carboplatin (GCb) (n=2), topotecan (n=2), FOLFOXIRI (n=1), and Carboplatin/Paclitaxel/Tislelizumab (n=1)...It also showed a positive impact on progression-free and overall survival, without compromising chemotherapy effectiveness or increasing toxicity. These findings highlight Trilaciclib's potential as a valuable adjunct to chemotherapy in appropriately selected patients."

Retrospective data • Review • Breast Cancer • Colorectal Cancer • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO (ASH 2025) - P3 | "We report updated efficacy and safety of Glofit-GemOxversus R-GemOx, with 3 years of follow-up, in patients with R/R DLBCL after ≥1 prior line of therapy (LOT)from the global Phase III STARGLO trial (NCT04408638).MethodsPatients were randomized 2:1 to either Glofit-GemOx (8 cycles plus 4 cycles glofitamab monotherapy) orR-GemOx (8 cycles) and stratified by number of prior LOT (1 vs ≥2) and refractoriness to last therapy.Following obinutuzumab pretreatment, glofitamab was given in Cycle 1 as weekly step-up doses(2.5/10mg), then 30mg target dose every 21 days from Cycle 2 Day 1. The safety profile remained consistent with the known risks of each study drug and wasmanageable. This updated analysis demonstrates the sustained remission and continued survivaladvantages that fixed-duration Glofit-GemOx offers for patients with R/R DLBCL."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy (ASH 2025) - P3 | "In SUNMO, Mosun-Pola provided benefits across multiple aspects of HRQoL compared withR-GemOx, particularly in maintaining/improving physical functioning, fatigue, lymphoma symptoms, andPN. Pts treated with Mosun-Pola achieved clinically meaningful improvements in PROs, with scoresexceeding the MCID in several domains and exhibiting a delay in deterioration of >1 year for physicalfunctioning, and >2 months for PN and lymphoma symptoms. Improved PROs with Mosun-Pola vs R-GemOx suggest benefits in HRQoL with chemotherapy-free bispecific antibody combinations."

Clinical • HEOR • B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Gynecologic Cancers • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral Neuropathic Pain

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma (ASH 2025) - P1 | "With universal prior rituximab exposure in pts withR/R LBCL, salvage strategies may be improved by incorporating novel agents instead of rituximabretreatment...All pts receive at least 2 cyclesof concurrent Mosun + platinum-based chemotherapy, with chemotherapy per treating physician (Arm A:dexamethasone, cytarabine, oxaliplatin [DHAX]; Arm B: ifosfamide, carboplatin, etoposide [ICE])...Pts receive 20mg IV dexamethasone prior to each C1-C2Mosun dose, with optional steroid premeds thereafter...Nine pts experienced CRS (all gr1; no tocilizumab required)... Mosun + DHAX/ICE demonstrated a manageable safety profile with low-grade CRS.Preliminary efficacy results reveal promising anti-lymphoma activity in a high-risk population, with highCR rate and no progressions after CR with relatively short follow-up. This regimen is encouraging forfurther study. Long-term efficacy data are awaited to better assess remission durability."

Clinical • B Cell Lymphoma • Cardiovascular • CNS Disorders • CNS Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Psychiatry • Septic Shock • Thrombocytopenia • Thrombosis • CD20

Dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in refractory or Relapsed Diffuse large B-cell lymphoma patients post-salvage therapy: A phase II study (ASH 2025) - P2 | "We previously investigated the efficacy of CD-R-GemOx, a dual epigenetic agent-primed immunochemotherapy regimen, consisting of chidamide,decitabine, rituximab, gemcitabine, and oxaliplatin, in this high-risk population...This emphasizes thecritical need to optimize the dual epigenetic immunochemotherapy approach to enhance patientoutcomes while mitigating adverse effects.Aims: This study aims to evaluate the efficacy and safety of a modified dual epigenetic primingimmunochemotherapy regimen, termed CAGM, consisting of chidamide, azacitidine, obinutuzumab, andmitoxantrone liposome, in R/R DLBCL patients who had failed salvage therapy. This ongoing, prospective, multicenter, open-label phase II study (NCT05823701) enrolledpatients with R/R DLBCL who had failed salvage therapy... This study demonstrates the favorable efficacy and significantly lower hematologicaltoxicities of the CAGM regimen in R/R DLBCL patients, offering a promising therapeutic option for..."

Clinical • P2 data • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Infectious Disease • Lymphoma • Mucositis • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor) (ASH 2025) - "Pts had a median 2 prior lines of therapy (LOT), 60% had primary refractorydisease, 53% had prior CART, and 4 received gemcitabine/oxaliplatin with BsAb...CRS was treated with steroids (n=8) and tocilizumab (n=11)...Future analysisof a larger pt cohort is needed to validate this finding. Our study supports the utilization of a RDES forglofit or epco when clinically warranted."

Clinical • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003 (ASH 2025) - P2/3 | "The phase 2/3 waveLINE-003 trial (NCT05139017) evaluated the safety and efficacy of ZV plusrituximab and gemcitabine-oxaliplatin (R-GemOx) in participants with R/R DLBCL...The median number of prior therapies was 2.0 with 7 (18%) pts receiving prior CAR-T, 7 (18%)receiving prior ASCT, and 2 (5%) received prior polatuzumab vedotin... After approximately 19 months of follow-up, ZV plus R-GemOX continues to demonstratepromising efficacy and acceptable safety in R/R DLBCL at the RP2D of ZV of 1.75 mg/kg plus R-GemOx. Nonew safety concerns were reported. The efficacy expansion phase of this trial randomizing participants toZV plus R-GemOx versus R-GemOx is currently ongoing."

P2/3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Septic Shock • ROR1

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups (ASH 2025) - P3 | "Glofit-GemOx demonstrated superior survival and response outcomes vs R-GemOx,regardless of prior LOT and age, particularly in the 2L setting including in pts with primary refractorydisease and early relapse. Safety was generally consistent in pt subgroups vs the overall population andin line with prior results."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population (ASH 2025) - P1/2 | "In R/RDLBCL, standard salvage therapy with gemcitabine plus oxaliplatin (GemOx) yielded a complete response(CR) rate of 25%, overall response rate (ORR) of 41%, median progression-free survival (mPFS) of 3.6 mo,and median overall survival (mOS) of 12.9 mo (Abramson JS, et al. Epcor + GemOx demonstrated sustained remissions of >2 y, prolonged PFS and OS, anddeep MRD negativity in challenging-to-treat 2L+ R/R DLBCL; these results are widely applicable to adiverse pt population across the US and Europe. With longer follow-up, the safety profile remainedconsistent with previous reports. These findings support the combinability of epcor with standard-of-carechemotherapy and offer an effective option for ASCT-ineligible pts, a population with otherwise limited txchoices."

Clinical • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Pancreatic Adenocarcinoma • Pancreatic Cancer • Respiratory Diseases

Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity (ASH 2025) - "MethodsWe performed a retrospective chart review on patients aged 18 and older receiving 5-FU-basedintravenous chemotherapy (including 5-FU, FOLFOXIRI, FOLFIRI, FOLFIRINOX) at a single academic centerfrom June 1, 2022 to June 1, 2024...Should ferritin be elevated, we advise clinicians to maintaina high index of suspicion for obstructive CAD and heart failure. Larger multi-institutional studies onbiomarkers predicting cancer therapy-related cardiovascular toxicity or treatment failure rates meritfuture consideration."

Congestive Heart Failure • Coronary Artery Disease • Gastrointestinal Cancer • Heart Failure

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL (ASH 2025) - "The median number ofprior treatment lines before bridging therapy was 2 (range 1-4).Bridging therapy consisted of glofitamab monotherapy (3 patients) or glofitamab combined withchemotherapy (GVM [gemcitabine, vinorelbine, mitoxantrone hydrochloride liposome] in 4patients; GemOx [gemcitabine, oxaliplatin] in 4 patients). These preliminary data suggest that BsAbs-containing bridging therapy prior toCD19-specific CAR-T therapy, either alone or combined with HDT/ASCT, is effective and safe inDLBCL. More detailed data will be presented at the conference."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • TP53